Abstract:Custom RNA base editing using the endogenous human Adenosine Deaminase Acting on RNA (ADAR) enzyme presents a promising approach for precision therapeutics, alleviating concerns of permanent DNA damage or immunogenicity from foreign bacterial proteins such as CRISPR/Cas. ADAR can be directed to act on therapeutic RNA targets by antisense guide RNAs (gRNAs) that create a substrate for ADAR′s adenosine-to-inosine (effectively A-to-G) deamination activity. Delivery of gRNAs via a DNA expression construct provided by Adeno-Associated Virus (AAV) might allow life-long duration of the therapy. However, a major challenge for RNA editing using gene-encoded gRNAs and endogenous levels of ADAR is achieving sufficient gRNA activity inside cells, especially in therapeutic situations where AAV delivery may provide as low as one viral genome per cell. Here we show that embedding antisense gRNAs into a U7 small nuclear RNA (snRNA) framework and adding hnRNP A1 binding domains greatly increases the efficiency of custom RNA editing. This increased editing efficiency allows for detectable RNA editing from a single genomic insertion of gRNA construct per cell, which enabled a pooled library screen of 750+ gRNA variations to further improve the SmOPT U7 hairpin system. The screen revealed critical residues responsible for RNA editing and generated new SmOPT and U7 hairpin variants that further boosted RNA editing. The final design, combined with an improved synthetic U7 promoter, resulted in up to 76% targeted editing with a single integrated copy of construct per cell, representing a 10- to 100-fold increase over existing circular gRNA approaches. Using systemic AAV delivery, we achieved an unprecedented 75% RNA editing in the total brain of a mouse model of Hurler syndrome. Our novel SmOPT U7 system also improved published antisense oligos for DMD exon skipping, currently in clinical trials, by up to 25-fold in differentiated myoblasts, and therefore represents a universal scaffold for ADAR-based RNA editing as well as other antisense RNA therapies.

Short-Chain Guide RNA for Site-Directed A-to-I RNA Editing

Robust RNA editing via recruitment of endogenous ADARs using circular guide RNAs

Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs

Site-specific regulation of RNA editing with ribose-modified nucleoside analogs in ADAR guide strands

Wobble base improves precision in RNA editing

Light-triggered site-directed RNA editing by endogenous ADAR1 with photolabile guide RNA

Nucleoside Analogs in ADAR Guide Strands Enable Editing at 5′-GA Sites

A Novel Engineered U7 Small Nuclear RNA Scaffold Greatly Increases and ADAR-Mediated Programmable RNA Base Editing

Development of a selection assay for small guide RNAs that drive efficient site-directed RNA editing

Leveraging Small Molecule-Induced Aptazyme Cleavage for Directed A-to-I RNA Editing

Generative machine learning of ADAR substrates for precise and efficient RNA editing

ADAR-mediated RNA Editing in Non-Coding RNA Sequences

Site-directed RNA editing by harnessing ADARs: advances and challenges

Rational Design of RNA Editing Guide Strands: Cytidine Analogs at the Orphan Position

Precision RNA base editing with engineered and endogenous effectors

Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides

A-to-I editing of coding and non-coding RNAs by ADARs

Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing

Leveraging Endogenous ADAR for Programmable Editing on RNA

Structural perspectives on adenosine to inosine RNA editing by ADARs

DNA editing in DNA/RNA hybrids by adenosine deaminases that act on RNA